[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sharp HealthCare\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100593381","rapid-diagnostics-for-genetic-disorders-in-neonates-100593381",false,"NCT07005700","Rapid Diagnostics for Genetic Disorders in Neonates","Development of Rapid Diagnostics for Genetic Disorders in Neonates Using a Novel Targeted Genomic DNA Sequencing Analysis Panel.","Inclusion Criteria: neonates of any gestational age.\n\n* Abnormality in routine neonatal screening test.\n* Unexplained neonatal hypotonia or neonate-onset seizures.\n* Unexplained and abnormal biochemical laboratory findings.\n* Skeletal dysplasia or joint problems.\n\nExclusion Criteria:\n\n* Parental refusal of consent to participate.\n* Provider refusal.\n* Any condition that, in the opinion of the investigator, would interfere with interpretation of study results.","ALL","1 Day","6 Months",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this study is to test a prototype genomic blood analysis for identifying rare diseases in infants hospitalized in the neonatal intensive care unit (NICU).\n\nThe main question it aims to answer is: Does the prototype accurately identify genetic variation(s) associated with an infant's health condition?\n\nResearchers will compare the prototype's gene identification to traditional genome sequencing methods of gene identification.\n\nParticipants will be asked to provide a very small (one-tenth of a teaspoon) sample of blood, one-time.",[27],"Acid Base Disorder","NOT_YET_RECRUITING","2025-05-27",{"date":31,"type":32},"2025-06-05","ACTUAL",{"date":34,"type":21},"2025-06-30",{"date":36,"type":21},"2027-05",{"name":38,"class":39},"Sharp HealthCare","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100514354","phase-3-nicu-antibiotics-and-outcomes-nano-follow-up-study-100514354","NCT05977400","NICU Antibiotics and Outcomes (NANO) Follow-up Study","NICU Antibiotics and Outcomes Follow-Up Study","NANO-FU","Inclusion Criteria: Families that have agreed to participate and are enrolled in the parent NANO trial will be eligible for the NANO follow-up study. There will be no exclusions for eligible children entering the follow-up study.\n\nParent NANO trial Criteria:\n\nI. Inclusion criteria: We will enroll newborn infants with gestational age of 23.0-30.6 weeks born to mothers 18 years or older at participating study sites. Only inborn infants at participating study sites will be eligible.\n\nII. Exclusion criteria:\n\n1. Infants at low risk for early onset sepsis-Infants born for maternal indications via caesarean section with rupture of membranes within 6 hours, without attempts to induce labor, and without concern for maternal infection\n2. Infants at high risk for early onset sepsis- Infants born to mothers with intrapartum fever (\\> 38ºC) or clinical diagnosis of chorioamnionitis (suspected or definite), infants born to mothers with proven Group B Streptococcus colonization or indication for intrapartum antibiotic prophylaxis that did not receive adequate antibiotic treatment according to specialty specific guidelines, (i.e., penicillin, ampicillin, cefazolin), infant born to mother with previous infant with GBS disease\u002Finfection\n3. Infants with respiratory insufficiency requiring invasive mechanical ventilation and fraction of inspired oxygen\\> 0.40 or non-invasive ventilation and fraction of inspired oxygen \\> 0.60 at time of randomization\n4. Infants with ongoing hemodynamic instability requiring vasopressors or more than one fluid bolus at time of randomization\n5. Clinician concern for sepsis due to physical exam findings or clinical history of mother or infant\n6. Major congenital anomalies\n7. Infants not anticipated to survive beyond 72 hours\n8. Infants who have received antibiotics prior to randomization.","23 Weeks","30 Weeks",{"count":52,"type":21},802,[54],"PHASE3","The NANO follow-up study is designed to determine whether a simple, cost-effective intervention- withholding antibiotics at birth- reduces clinically relevant outcomes such as behavioral and neurological impairment at 2 years of age. This study will be the largest study evaluating the effects of early antibiotics in children with comprehensive measures of neurodevelopment linked to genomic variants and microbiota interactions.",[57,58,59],"Premature Birth","Antibiotics","Neurodevelopment","2023-07-28",{"date":62,"type":32},"2023-08-04",{"date":64,"type":21},"2024-04",{"date":66,"type":21},"2029-03",{"name":38,"class":39},15,""]